French Observatory of Rare Malignant Tumors of the Ovary
NCT ID: NCT01304043
Last Updated: 2012-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
204 participants
OBSERVATIONAL
2002-01-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
NCT05204342
Genomic BRCA and Extensive ovArian Cancer Testing
NCT04027868
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351
Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers
NCT05267912
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* to proceed in a centralised examination of histologic laminas
* to reach in the long-term and homogenous follow-up of the patients
* to follow-up the long-term toxicities of the treatments given
* to analyse and follow-up the later fertility of the patients
* to evaluate the interest of setting a multi-disciplinary discussion forum on the Web
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chemotherapies protocols
Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* germinal or sexual cords ovary tumors histologically proven
* first line or relapse treatment
* written informed consent
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabelle Ray-Coquard, Physician
Role: PRINCIPAL_INVESTIGATOR
GINECO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
information for patients, discussion forum about "difficult" cases, therapeutic strategy for patients presenting rare ovarian tumor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMRO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.